Study Comparing Formulations of Bazedoxifene/Conjugated Estrogens
Information source: Wyeth
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: bazedoxifene/conjugated estrogens combination (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Wyeth Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Wyeth
Summary
The primary purpose is to determine bioavailability of Bazedoxifene/conjugated estrogen
formulations for future testing purposes.
Clinical Details
Official title: An Open-Label, Single-Dose, Non-Randomized, 4-Period Crossover Bioavailability Study of Bazedoxifene Contained in Bazedoxifene/Conjugated Estrogen Tablets Administered to Healthy Postmenopausal Women
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Crossover Assignment
Primary outcome: Bioavailability
Secondary outcome: Safety & tolerability
Eligibility
Minimum age: 45 Years.
Maximum age: 70 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Healthy, post menopausal women ages 45 to 70
Exclusion Criteria:
- Male subjects
Locations and Contacts
Additional Information
Starting date: October 2007
Ending date: November 2007
Last updated: December 18, 2007
|
